Radiology

Weill Cornell Medicine has received a projected $4 million grant from the National Cancer Institute, part of the National Institutes of Health, to conduct a clinical trial testing whether a new imaging approach could reduce the need for biopsies to monitor prostate cancer.

A new AI-based system for analyzing images taken over time can accurately detect changes and predict outcomes, according to a study led by investigators at Weill Cornell Medicine, Cornell’s Ithaca campus and Cornell Tech.

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

Weill Cornell Medicine researchers have received a $6.2 million, five-year grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution Positron Emission Tomography (PET) scanner that can detect the earliest stages of Alzheimer’s disease.

Researchers at Weill Cornell Medicine, Cornell Tech and Cornell's Ithaca campus have demonstrated the use of AI-selected natural images and AI-generated synthetic images as neuroscientific tools for probing the visual processing areas of the brain.

Dr. Vanessa Bellat, an assistant professor of chemistry in radiology and an affiliate of the Molecular Imaging and Innovations Institute (MI3) at Weill Cornell Medicine, has been awarded a $2 million, four-year R37 MERIT grant from the National Cancer Institute, part of the National Institutes of Health. She will be developing a new therapeutic approach using nanofibers that selectively deliver drugs to the lungs to treat metastatic tumors. 

The program has prepared Weill Cornell Medicine faculty members to grow into institutional leaders. 

Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical research, education and care May 17-18 during Weill Cornell Medicine’s commencement activities.

Weill Cornell Medical College student Pauline Flaum-Dunoyer is a natural storyteller and historian.

The psychedelic drugs LSD and psilocybin activate serotonin receptors on brain cells in a way that reduces the energy needed for the brain to switch between different activity states, according to a study led by Weill Cornell Medicine researchers.

The degree to which the brain’s wiring aligns with its patterns of activity can vary with sex and age, and may be genetic, suggests a study published by Weill Cornell Medicine investigators. 

Dr. Geraldine McGinty, an esteemed clinical operations strategist, administrator and radiologist, has been appointed senior associate dean for clinical affairs at Weill Cornell Medicine

Medicines that contain radioactive isotopes—known as radiopharmaceuticals—are used to treat cancer and to help physicians diagnose a wide variety of conditions through imaging. But while radiopharmaceuticals are a standard and invaluable medical tool in the field of nuclear medicine, synthesizing them can be challenging.